Introduction
Among all diseases, cancer has been the one on which the greatest efforts have been focused (1). Cancer is the second leading cause of death in the world considering that 9.6 million people have died worldwide in 2018 (2). Among all types of cancers, lung cancer is one of the most common cancers in the world and it accounts for 1.35 million cases out of every 10.9 million newly diagnosed cancers. It is also the leading cause of cancer-related death worldwide. Therefore, 1.18 million cases out of every 6.7 million cancer-related deaths belong to lung cancer (3, 4). According to a report released by the World Health Organization (WHO) in 2018, 1.760.000 people have died from lung cancer, and it is predicted that 658,140 deaths will be added to the above figure by 2030 (5). Lung cancer is the first most common cancer in middle-income countries and the second most common cancer in high-income countries (4). Lung cancer is the fourth most common cancer in Iran and the first leading cause of cancer deaths in Iran considering the age-specific death rate of 19.5 per 10,000 people (6). According to the American Cancer Society, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are two types of lung cancer, with NSCLC accounting for 85% of lung cancers (7, 8). Adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are the three main types of NSCLC (9).

Survival rate of cancer patients is one of the important indicators in disease control and evaluation of therapeutic methods (10). The 5-year survival rate of lung cancer patients in developed countries has been reported to be between 14.4% and 22.6% (11). Taghipour Zahir and
Mirtalebi reported an average survival time of 8.5 months for lung cancer patients. They concluded that only 25% of patients survived more than one year (12). Grose et al reported an average survival time of 6.5 months and one-year survival rate of 30% for lung cancer patients (13). Santoro et al obtained an average survival time of 15.7 months. They estimated the average survival time of 14.9 and 22.1 months for smokers and non-smokers with lung cancer, respectively (14). Since smoking is one of the most important risk factors for lung cancer, smokers are 20 times more likely to develop lung cancer than non-smokers. Smoking accounts for 71% of deaths occurring in lung cancer patients. Age, sex, stage of disease, tumor size, type of treatment, and the number of lymph nodes involved are other factors influencing the survival of lung cancer patients (15-18). Considering the high incidence of lung cancer and its poor prognosis in spite of advances in the treatment of the disease and since no study has been conducted to estimate the survival of patients with lung cancer in Hamadan, the present study aimed to evaluate the survival of patients with lung cancer and factors affecting the survival of these patients in Hamadan.

Materials and Methods
This retrospective cohort study was performed on 157 patients referred to Imam Khomeini specialized clinic in Hamadan. The present study was carried out on all patients diagnosed with cancer during 2003-2017. The study population included all patients with pathologic stage of lung cancer and those having relevant data. All demographic information including age at diagnosis, sex, occupation, and smoking status and paraclinical information including tumor type, tumor location, stage of disease, degree of differentiation, number of lymph nodes involved, metastasis (yes/no), site of metastasis, type of treatment, type of surgery, date of diagnosis, and the date of death of the patients were extracted to achieve the desired goals of the present study. The current study also investigated the survival of all lung cancer patients from diagnosis until death or end of the study. Patients’ death data were collected from Death Registration Center, Deputy of Health of Hamadan Province and if no information was available, the latest information on their life status until March 2017 was obtained by contacting first-degree relatives of patients (phone number registered in the patient’s case). Kaplan-Meier method was also used to determine the survival rate and log-rank method was used to compare the survival of different levels of variables. Data analysis was also carried out using SPSS version 23.0 and STATA version 14.0. \( P < 0.05 \) was considered statistically significant in all tests.

Results
A total of 157 patients with a definitive diagnosis of lung cancer referred to Imam Khomeini specialized clinic in Hamadan from 2003 to 2016. The mean age of the patients was 61.84 years. Of the 157 patients with lung cancer, 135 (86%) were male and 22 (14%) were female. A total of 54 patients (34.4%) had a history of smoking. The frequency of SCLC and NSCLC was 37.3% and 62.7%, respectively, and SCSC was the most frequent tumor in the NSCLC group. The most common tumor sites included the upper lobe of right lung (22.2), right bronchus (16.6), and left bronchus (15.5%). A total of 82 patients (95.3%) had reached the metastatic stage. Chemotherapy has been the most commonly used treatment for patients. Moreover, a total of 54 patients (39.3%) had died of the end of follow-up. Other demographic and clinical characteristics of patients are listed in Table 1.

According to Kaplan-Meier survival diagram, the mean and median overall survival times of patients were 15 and 11 months, respectively (Figure 1). The results of the log-rank test showed a significant difference between the survival of patients who had reached the metastatic stage (47 months) and those who had not reached metastasis (10 months). The result of the log-rank test also confirms this finding \( (P = 0.001) \). Therefore, there is a significant relationship between metastasis and the survival of lung cancer patients. The results of log-rank test showed that in addition to metastasis, site of metastasis was also effective in the survival rate (Table 2). Patients whose cancer has spread to the brain had a higher survival rate than patients who had metastases to the bone or liver \( (P = 0.004) \). Furthermore, the variables of age, type of treatment, stage of disease, and tumor location had no significant effect on the survival of patients with lung cancer \( (P > 0.05; \text{Table 2}) \).

Discussion
To date, there have been many studies on different aspects of lung cancer. In this study, the results of data analysis indicated that the variables of metastasis and site of metastasis significantly affected the survival of patients. The mean and median survival rates calculated in the present study are close to those obtained in studies by Julka et al, Crvenkova, and Chen et al (16, 19, 20). Some
studies reported lower survival rates than those estimated in the present study; for example, the mean and median survival time in the study by Abazari et al were calculated to be 13 and 4.8 months, respectively (1). In addition, the median survival rate estimated in the present study is lower than that of studies in other countries, including Germany and the United States, indicating that the survival of patients with lung cancer is lower in Iran than in some parts of the world and is one of the most important reasons may be the late diagnosis of patients with lung cancer in Iran due to the lack of an appropriate screening program. For example, the median survival time of German SCLC patients has increased to 46 months because of timely diagnosis and treatment (21). Moreover, the median survival time of patients with lung cancer in the United States has also increased in recent decades, reaching from 12.4 months to 14.8 months, which can be attributed to the advances of treatment strategies such as radiotherapy and chemotherapy in this country (22, 23).

The mean age at diagnosis in this study was 61.84 years, which is consistent with the results of many studies in Iran and other countries (1, 19, 24, 25). The results of the present study indicate that the presence of metastasis is an important and effective factor in the survival of patients with lung cancer, which indicates a decrease in survival rate in patients with metastasis cancer. Therefore, the median survival time of patients who did not reach the metastatic stage was significantly higher than those who reached metastases. This may be due to poor prognosis and lack of a proper response

| Variable | Levels | Frequency |
|----------|--------|-----------|
| Gender (n=157) | Male | 135 |
| | Female | 22 |
| Age (n=157) | ≤ 60 years | 68 |
| | >60 years | 89 |
| Smoking history (n=62) | Yes | 54 |
| | No | 8 |
| Tumor type (n=134) | SCLC | 50 |
| | Adenocarcinoma | 30 |
| | SCC | 51 |
| | Large cell carcinoma | 3 |
| Primary tumor location (n=90) | Right bronchus | 15 |
| | Left bronchus | 14 |
| | Right upper lobe | 20 |
| | Right middle lobe | 3 |
| | Right inferior lobe | 12 |
| | Left upper lobe | 13 |
| | Left inferior lobe | 11 |
| | Others | 2 |
| Metastasis (n=86) | Yes | 82 |
| | No | 4 |
| Metastatic site (n=81) | Liver | 12 |
| | Brain | 16 |
| | Bone | 29 |
| | Lymph nodes | 2 |
| | Liver and bone | 3 |
| | Brain and bone | 2 |
| | Others | 1 |
| | Unknown | 16 |
| Pathologic stage (n=82) | I | 1 |
| | II | 2 |
| | III | 5 |
| | IV | 74 |
| Type of treatment (n=157) | Chemotherapy | 101 |
| | Radiotherapy | 8 |
| | Chemotherapy and radiotherapy | 33 |
| | Chemotherapy and surgery | 5 |
| | All 3 types of treatment | 3 |
| | Unknown | 7 |

Table 2. Comparison of Survival Rates at the Levels of the Variables Considered in the Present Study

| Variable | Category | Median Survival Time (mon) | Log-Rank Test |
|----------|----------|---------------------------|--------------|
| Sex | Male | 13 | 0.963 |
| | Female | 11 | |
| Age at diagnosis | ≤ 60 years | 14 | 0.226 |
| | >60 years | 11 | |
| Tumor location | Right bronchus | 11 | |
| | Left bronchus | 12 | |
| | Right upper lobe | 10 | |
| | Right middle lobe | 11 | |
| | Right inferior lobe | 10 | |
| | Left upper lobe | 13 | |
| | Left inferior lobe | 14 | |
| Stage of disease | I, II, III | 12 | 0.061 |
| | IV | 9 | |
| Metastasis | Yes | 10 | >0.001 |
| | No | 47 | |
| Site of metastasis | Liver | 9 | 0.004 |
| | Brain | 10 | |
| | Bone | 7 | |
| | Others | 6 | |
| Chemotherapy | Yes | 11 | 0.574 |
| | No | 14 | |
| Radiotherapy and chemotherapy | Yes | 12 | 0.994 |
| | No | 11 | |
| Surgery | Yes | 10 | 0.811 |
| | No | 12 | |
to treatment strategies at this stage. Previous studies have also shown that metastasis is an effective variable in the survival of patients with lung cancer (1, 24, 26). Kasapoglu et al stated that the risk of death in metastatic lung cancer patients with pyloric involvement is twice higher compared to patients without metastasis (18). In addition, the results of the study by Abazari et al showed that the median survival of metastatic and non-metastatic patients were 5.8 and 12.2 months, respectively, and the risk of death in metastatic patients is 1.28 times higher compared to patients without metastases (1). The results of the present study also revealed that the site of metastasis is also one of the factors affecting the survival of lung cancer patients. The survival rate varies depending on the site of metastasis, and patients with brain metastasis have a higher median survival rate than other patients. These results are consistent with the results of a study by Babanejhad et al They also emphasized the importance of the site of metastasis in the survival of patients and concluded that there was no significant difference between the survival of lung cancer patients with bone metastasis and those without metastases; however, the risk of death in lung cancer patients with brain metastases is 1.73 times higher compared to patients who did not reach the metastatic stage (24). The present study also showed no significant difference between the survival of patients undergoing different treatment strategies and those who did not receive any treatment. However, Zahair Taghipour & Mirzalebi (12) and Kasapoglu et al (18) reported that the type of treatment was an effective factor in the survival of patients, indicating that patients undergoing chemotherapy and radiotherapy or surgery and chemotherapy had a higher median survival rate than others. This may be due to the small number of lung cancer patients in this study considering that we accessed to medical information of a small number of lung cancer patients referred to the clinic of Imam Khomeini Hamadan. However, this issue should be addressed in studies with a larger sample size.

The results of many studies showed that variables of age at diagnosis and stage of the disease are important factors in the prognosis of patients. The survival rate decreases with an increase in the age at diagnosis and higher survival rate is expected in patients diagnosed at a younger age and are at an early stage (1, 12, 24). However, these variables had no significant effect on survival, which could be attributed to inaccurate recording of pathological and demographic data of the patients and lack of access to important variables. It was not possible to analyze the relationship between survival rate and smoking status, which is one of the important factors in the survival of lung cancer patients. Other limitations of the present study include incomplete medical records, changes in patients’ phone numbers, and inaccessibility of some patients, and the poor co-operation of some relatives in providing patient information in some cases.

**Conclusion**

The results of the present study showed that the median survival of lung cancer patients is relatively low, and since metastasis is an important factor adversely affecting the survival of patients, it is essential to diagnose the disease as early as possible using an organized screening and periodic referral program, thereby increasing the life expectancy of patients by identifying those at risk and initiating treatment before the disease progression.

**Conflict of Interest Disclosures**

The authors declare that they have no conflict of interests.

**Acknowledgments**

The authors hereby would like to express their thanks to the respected Vice Chancellor for Research and Technology.

**Ethical Statement**

This article was taken from the research project approved by the Research Council of the University of Medical Sciences (9603161717) with a specific ID of the Ethics Committee (IR. UMSHA.REC.1396.206).

**Authors’ contributions**

FG and GhR designed and performed the research. Data analysis, interpretation and manuscript preparation was performed by MA and ZB. All authors contributed to the final version of the manuscript and approved the final manuscript.

**Funding/Support**

This study was a part of project (with ID code 9603161717) and it was supported by Vice-Chancellor of Research and Technology, Hamadan University of Medical Sciences.

**Informed Consent**

Not applicable.

**References**

1. Abazari M, Gholamnejad M, Roshanaei G, Abazari R, Roosta Y, Mahjub H. Estimation of survival rates in patients with lung cancer in west Azerbaijan, the northwest of Iran. Asian Pac J Cancer Prev. 2015;16(9):3923-6. doi: 10.7314/apjcp.2015.16.9.3923.
2. World Health Organization (WHO). Cancer. WHO; 2019. [updated September 2018]; Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
3. Bahader Y, Jazieh A-R. Epidemiology of lung cancer. Ann Thorac Med. 2008;3(6):63-7.
4. International Agency for Research on Cancer (IARC). World Cancer Factsheet. Geneva: WHO; 2014.
5. International Agency for Research on Cancer (IARC). Estimated number of deaths from 2018 to 2030, lung, both sexes, all ages. Geneva: WHO; 2018; [updated 2018]; Available from: http://gco.iarc.fr/tomorrow.
6. International Agency for Research on Cancer (IARC). Estimated number of deaths in 2018, Asia, Iran, Islamic Republic of, both sexes, all ages. Geneva: WHO; 2018. [updated 2018]; Available from: http://gco.iarc.fr/today/online-analysis-table.
7. Macdonald F, Ford CH, Casson AG. Molecular Biology of Cancer. 2nd ed. London: BIOS Scientific Publishers; 2004.
8. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584-94. doi: 10.4065/83.5.584.
9. Hussain SP, Hofseth LJ, Harris CC. Tumor suppressor genes:
at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer. 2001;34 Suppl 2:S57-15. doi: 10.1016/S1695-5101(01)00339-7.

10. Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning Text. New York, NY: Springer; 2005.

11. International Agency for Research on Cancer (IARC). Age-standardized incidence, mortality rates (25-99 years) and 5-year net survival (15-99 years) in 2014, Lung, both sexes. Geneva: WHO; 2018. [updated 2018]; Available from: http://gco.iarc.fr/survival/survmark.

12. Taghipour Zahir S, Mirtalebi M. Survival of patients with lung cancer, Yazd, Iran. Asian Pac J Cancer Prev. 2012;13(9):4387-91. doi: 10.7314/apjcp.2012.13.9.4387.

13. Grose D, Devereux G, Brown L, Jones R, Sharma D, Selby C, et al. Simple and objective prediction of survival in patients with lung cancer: staging the host systemic inflammatory response. Lung Cancer Int. 2014;2014:731925. doi: 10.1155/2014/731925.

14. Santoro IL, Ramos RP, Franceschini J, Jannik S, Fernandes AL. Non-small cell lung cancer in never smokers: a clinical entity to be identified. Clinics (Sao Paulo). 2011;66(11):1873-7. doi: 10.1590/s1807-59322011001100005.

15. Abazari M, Abazari R, Roshanaei G, Gholamnejad M, Mahjub H. Evaluation of prognostic variables for classifying the survival in lung cancer patients using the decision tree. Journal of Sabzevar University of Medical Sciences. 2015;22(4):549-56. [Persian].

16. Crvenkova S. Influence of prognostic factors on survival in locally advanced non-small cell lung cancer patients treated with combination of chemoradiotherapy. J Nucl Med Radiat Ther. 2014;6:200. doi: 10.4172/2155-9619.1000200.

17. Hosseini M, Naghan PA, Karimi S, SeyedAlinaghi S, Bahadori M, Khodadad K, et al. Environmental risk factors for lung cancer in Iran: a case-control study. Int J Epidemiol. 2009;38(4):989-96. doi: 10.1093/ije/dyp218.

18. Kasapoglu US, Arinc S, Gungor S, Irmak I, Guney P, Aksoy F, et al. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions. Clin Respir J. 2016;10(6):791-9. doi: 10.1111/crj.12292.

19. Chen YM, Fang YT, Lai CH, Rau KM, Huang CH, Chang HC, et al. A survival scoring system for non-small cell lung cancer patients with de novo bone metastases. PLoS One. 2016;11(12):e0167923. doi: 10.1371/journal.pone.0167923.

20. Julka PK, Sharma DN, Madan R, Mallick S, Benson R, Kunhi PH, et al. Patterns of care and survival among small cell lung cancer patients: experience from a tertiary center in India. J Egypt Natl Canc Inst. 2017;29(1):47-51. doi: 10.1016/j.jnci.2016.10.001.

21. Käsmann L, Bolm L, Janssen S, Rades D. Prognostic factors and treatment of early-stage small-cell lung cancer. Anticancer Res. 2017;37(3):1533-7. doi: 10.21873/anticanceres.11482.

22. Lou Y, Dholaria B, Sojano A, Hodge D, Cochuyt J, Manochakian R, et al. Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018;7(10):4932-42. doi: 10.1002/cam4.1749.

23. Schabath MB, Nguyen A, Wilson P, Sommerer KR, Thompson ZJ, Chiappori AA. Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients. Lung Cancer. 2014;86(1):14-21. doi: 10.1016/j.lungcan.2014.07.014.

24. Babanejad F, Yazdani Charati J, Shahbankhani B, Alyannejad R, Saber S, Ghasemkhani S. Survival analysis of patients with lung cancer using cox regression model. Journal of Mazandaran University of Medical Sciences. 2018;28(161):66-74. [Persian].

25. Hsieh CP, Hsieh MJ, Wu CF, Fu JY, Liu YH, Wu YC, et al. Prognostic factors in non-small cell lung cancer patients who received neoadjuvant therapy and curative resection. J Thorac Dis. 2016;8(7):1477-86. doi: 10.21037/jtd.2016.05.57.

26. Tas F, Ciftci R, Kilic L, Karabulut S. Age is a prognostic factor affecting survival in lung cancer patients. Oncol Lett. 2013;6(5):1507-13. doi: 10.3892/ol.2013.1566.